Evidence map›Paper›PMID 35696734›Full record

ArticleBlood advances2022

Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis.

Kenneth I Ataga, Qingning Zhou, Santosh L Saraf, Jane S Hankins, Emily J Ciccone, Laura R Loehr, Allison E Ashley-Koch, Melanie E Garrett, Jianwen Cai, Marilyn J Telen and 1 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07175051 (Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  7. Article
  8. Article
  9. Sickle Cell Disease and CKD: An Update.American journal of nephrology · 2024
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenneth I AtagaCenter for Sickle Cell Disease, University of Tennessee Health Scienter Center, Memphis, TN.ORCID 0000-0002-4501-9982
Qingning ZhouDepartment of Mathematics and Statistics, University of North Carolina at Charlotte, Charlotte, NC.ORCID 0000-0002-9499-9040
Santosh L SarafDivision of Hematology/Oncology, University of Illinois, Chicago, IL.ORCID 0000-0002-8584-4194
Jane S HankinsDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-4439-7321
Emily J CicconeDivision of Infectious Diseases and.ORCID 0000-0003-2445-8473
Laura R LoehrDivision of General Medicine and Clinical Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Allison E Ashley-KochDuke Molecular Physiology Institute, Duke University Medical Center, Durham, NC.
Melanie E GarrettDuke Molecular Physiology Institute, Duke University Medical Center, Durham, NC.
Jianwen CaiDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Marilyn J TelenDivision of Hematology, Duke University Medical Center, Durham, NC; and.ORCID 0000-0003-3809-1780
Vimal K DerebailUNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-7662-7497

Funding

Pulmonary Hypertension in SCDR01HL079915 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2005 to 2008
$6.7M
Outcome Modifying Genes in Sickle Cell DiseaseR01HL068959 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2001 to 2005
$3.6M
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER)R01HL159376 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ATAGA, KENNETH I, SARAF, SANTOSH · 2021 to 2025
$3.2M
THE ASSOCIATION OF BIOMARKERS OF ENDOTHELIAL FUNCTION WITH PROSPECTIVE CHANGES IN KIDNEY FUNCTION IN SICKLE CELL ANEMIAR01FD006030 · FDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ATAGA, KENNETH I · 2017 to 2021
$2.0M
Pathways of Cell-Free Hemoglobin in Sickle Cell NephropathyR01HL153161 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2020 to 2024
$2.0M
Transcriptomic, therapeutic and genetic investigations of sickle cell nephropathyR01DK110104 · NIDDK · DUKE UNIVERSITY · PI ASHLEY-KOCH, ALLISON E, DAVIS, ERICA ELLEN · 2016 to 2018
$716k
FDA HHS R01 FD006030NHLBI NIH HHS R01 HL068959NHLBI NIH HHS R01 HL079915NHLBI NIH HHS R01 HL153161NHLBI NIH HHS R01 HL159376NIDDK NIH HHS R01 DK110104
6 · The paper itself

Abstract

Glomerular hyperfiltration is common in young sickle cell anemia patients and precedes development of overt kidney disease. In this multicenter pooled cohort, we characterized hyperfiltration and its decline to normal range in adult patients. Glomerular filtration rate (GFR) was estimated using the creatinine-based 2009 CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation omitting race adjustment and the 2021 CKD-EPI equation. Using CKD-EPI-2009, 506 patients had baseline estimated GFR (eGFR) ≥90 mL/min per 1.73 m2, median age of 24 (interquartile range [IQR], 19-34) years and 5.17 years of follow-up. The prevalence of hyperfiltration (eGFR ≥140 and ≥130 mL/min per 1.73 m2 for men and women, respectively) was 38.3%. Using CKD-EPI-2009, baseline hyperfiltration was less likely with older age (odds ratio [OR], 0.78; 95% confidence interval [CI], 0.73-0.83; P < .0001), male sex (OR, 0.32; 95% CI, 0.18-0.58; P = .0002), and higher weight (OR, 0.96; 95% CI, 0.94-0.99; P = .001). Using CKD-EPI-2021, hyperfiltration was similarly less likely with older age (OR, 0.75; 95% CI, 0.70-0.81; P < .0001), male sex (OR, 0.24; 95% CI, 0.13-0.44; P < .0001), and higher weight (OR, 0.97; 95% CI, 0.95-0.99; P = .004). In patients with baseline hyperfiltration, eGFR declined to normal values at a median age of 26.2 years. Using CKD-EPI-2009, this decline was associated with male sex (HR, 2.20; 95% CI, 1.26-3.87; P = .006), systolic blood pressure (hazard ratio [HR], 1.02; 95% CI, 1.01-1.04; P = .01), and hydroxyurea use (HR, 1.74; 95% CI, 1.002-3.03; P = .05). Using CKD-EPI-2021, decline of eGFR to normal was only associated with male sex (HR, 3.39; 95% CI, 2.01-5.69; P < .0001). Decline to normal eGFR range from hyperfiltration occurs earlier in males, those on hydroxyurea, and with higher systolic blood pressure.

Indexed as

Anemia, Sickle CellRenal Insufficiency, ChronicAdultFemaleGlomerular Filtration RateHumansHydroxyureaLongitudinal StudiesMaleYoung AdultHydroxyurea

Identifiers

PMID35696734
PMCPMC9636315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.